[Valve protheses and anti-vitamin K. Biological study in patients given weak and strong doses of anticoagulants].
57 patients with Björk aortic valves had an in-depth study of their coagulation carried out. It seems that the well-anticoagulated group (39 patients) had more marked haemolysis, had a higher mean level of fibrinogen and PDF, but less biological signs of activation of fibrinolysis than the group who were non- or mildly-anticoagulated (18 patients). The increased platelet aggregation, which is often noted, was correlated with the signs of haemolysis, or of activation of the breakdown of fibrinogen. Apart from the problem of haemolysis, anticoagulant treatment appears biologically to be a moderating factor in the activation of the breakdown of fibrinogen and, by this means, of the utilisation of clotting factors.
D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology*; D001021:Aortic Valve; D001792:Blood Platelets / Q000187:drug effects; D005340:Fibrinogen / Q000378:metabolism; D006350:Heart Valve Prosthesis; D006461:Hemolysis / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D014812:Vitamin K; D005340:Fibrinogen
Prothèses valvulaires et anti-vitamines K. Etude biologique chez les sujets faiblement et fortement anticoagulés